B-cell lymphoma epidemiology and demographics: Difference between revisions
No edit summary |
Adnan Ezici (talk | contribs) No edit summary |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{B-cell lymphoma}} | {{B-cell lymphoma}} | ||
{{CMG}} | {{CMG}} ; {{AE}} {{Adnan Ezici}} | ||
==Overview== | ==Overview== | ||
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most of the [[Non-Hodgkin lymphomas]]. The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide. The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry. In the year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000. In the year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000. | |||
==Epidemiology and Demographics== | |||
==Demographics== | |||
===Incidence=== | |||
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref> | |||
===Case-fatality rate/Mortality rate=== | |||
In the year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In the year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref> | |||
===Age=== | |||
[[Non-Hodgkin lymphoma]] (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., [[Burkitt lymphoma]]) show a bimodal age distribution. [[Hodgkin's lymphoma]] has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref> | |||
===Race=== | |||
In the US, [[Non-Hodgkin lymphoma]] (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. [[Hodgkin's lymphoma]] shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.<ref name="pmid22241896">{{cite journal |vauthors=Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC |title=Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis |journal=Ann Oncol |volume=23 |issue=8 |pages=2128–2137 |date=August 2012 |pmid=22241896 |doi=10.1093/annonc/mdr578 |url=}}</ref> | |||
===Gender=== | |||
Men are more commonly affected by [[Non-Hodgkin lymphoma]] (NHL) than women. The male to female ratio is approximately 2 to 1, however, it's known that the male to female ratio is up to 4 in certain subtypes of NHL<ref name="pmid25386354">{{cite journal |vauthors=Horesh N, Horowitz NA |title=Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy |journal=Rambam Maimonides Med J |volume=5 |issue=4 |pages=e0038 |date=October 2014 |pmid=25386354 |pmc=4222427 |doi=10.5041/RMMJ.10172 |url=}}</ref><ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Men are more commonly affected by [[Hodgkin's lymphoma]] than women. The male to female ratio is approximately 3 to 2.3, however, it's known that the male to female ratio varies depending on the age. In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males with the M/F ratio of approximately 0.8. <ref name=NCI>{{cite web | title = National Caner Institute Childhood Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#cit/section_1.3}}</ref><ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref> | |||
===Region=== | |||
The majority of endemic [[Burkitt Lymphoma]], a subtype of NHL, cases are reported in subequatorial Africa.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Countries with the highest incidence (age-standardized) of [[Hodgkin's lymphoma]] include Lebanon, Greece, and Montenegro.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 19: | Line 29: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
Latest revision as of 09:59, 20 February 2022
|
B-cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
B-cell lymphoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of B-cell lymphoma epidemiology and demographics |
|
Risk calculators and risk factors for B-cell lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]
Overview
B-cell lymphomas include both Hodgkin's lymphomas and most of the Non-Hodgkin lymphomas. The incidence of non-Hodgkin lymphoma is approximately 18.6 per 100,000 individuals worldwide. The incidence of Hodgkin's lymphoma is approximately 2-3 per 100,000 individuals in populations of European ancestry. In the year 2018, the mortality rate of non-Hodgkin lymphoma is approximately 5.1/100,000. In the year 2017, the mortality rate of Hodgkin's lymphoma is approximately 0.41/100,000.
Epidemiology and Demographics
Incidence
The incidence of non-Hodgkin lymphoma is approximately 18.6 per 100,000 individuals worldwide.[1] The incidence of Hodgkin's lymphoma is approximately 2-3 per 100,000 individuals in populations of European ancestry.[2]
Case-fatality rate/Mortality rate
In the year 2018, the mortality rate of non-Hodgkin lymphoma is approximately 5.1/100,000.[1] In the year 2017, the mortality rate of Hodgkin's lymphoma is approximately 0.41/100,000.[3]
Age
Non-Hodgkin lymphoma (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., Burkitt lymphoma) show a bimodal age distribution. Hodgkin's lymphoma has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.[3]
Race
In the US, Non-Hodgkin lymphoma (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.[1]. Hodgkin's lymphoma shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.[4]
Gender
Men are more commonly affected by Non-Hodgkin lymphoma (NHL) than women. The male to female ratio is approximately 2 to 1, however, it's known that the male to female ratio is up to 4 in certain subtypes of NHL[5][1]. Men are more commonly affected by Hodgkin's lymphoma than women. The male to female ratio is approximately 3 to 2.3, however, it's known that the male to female ratio varies depending on the age. In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males with the M/F ratio of approximately 0.8. [6][3]
Region
The majority of endemic Burkitt Lymphoma, a subtype of NHL, cases are reported in subequatorial Africa.[1]. Countries with the highest incidence (age-standardized) of Hodgkin's lymphoma include Lebanon, Greece, and Montenegro.[3]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P (January 2021). "Epidemiology of Non-Hodgkin's Lymphoma". Med Sci (Basel). 9 (1). doi:10.3390/medsci9010005. PMC 7930980 Check
|pmc=value (help). PMID 33573146 Check|pmid=value (help). - ↑ Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL (July 2020). "Hodgkin lymphoma". Nat Rev Dis Primers. 6 (1): 61. doi:10.1038/s41572-020-0189-6. PMID 32703953 Check
|pmid=value (help). - ↑ 3.0 3.1 3.2 3.3 Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z (October 2019). "Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study". J Hematol Oncol. 12 (1): 107. doi:10.1186/s13045-019-0799-1. PMC 6805485 Check
|pmc=value (help). PMID 31640759. - ↑ Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC (August 2012). "Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis". Ann Oncol. 23 (8): 2128–2137. doi:10.1093/annonc/mdr578. PMID 22241896.
- ↑ Horesh N, Horowitz NA (October 2014). "Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy". Rambam Maimonides Med J. 5 (4): e0038. doi:10.5041/RMMJ.10172. PMC 4222427. PMID 25386354.
- ↑ "National Caner Institute Childhood Hodgkin Lymphoma Treatment".